Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control

CONCLUSIONS: Salvage HDR-BT 12 × 2 is a feasible and well-tolerated treatment, with acceptable toxicity rates for men with locally recurrent prostate cancer, who failed after HDR-BT with 19 Gy. Moreover, PSA kinetics and cancer control after salvage treatment suggest that this strategy might be efficacious in this clinical setting.PMID:34025731 | PMC:PMC8117711 | DOI:10.5114/jcb.2021.103581

Source: Journal of Contemporary Brachytherapy - May 24, 2021 Category: Cancer & Oncology Authors: Esther Mayrata Jose Maria Espinosa David B üchser Francisco Casquero Fernan Su árez Alba Gonz ález Pablo Minguez Jose Fernando P érez I ñigo San Miguel Jon Cacicedo Alfonso G ómez-Iturriaga Source Type: research